Padmaja Venuturumilli

Dr. Padmaja Venuturumilli

Oncology
3577 West 13 Mile Road, Suite 103, 
Royal Oak, MI 
On Staff At
Accepting New Patients
Offers Telehealth
35 Years of Experience
3577 West 13 Mile Road, Suite 103, 
Royal Oak, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Padmaja Venuturumilli is an Oncologist in Royal Oak, Michigan. Dr. Venuturumilli has been practicing medicine for over 35 years and is rated as an Experienced provider by MediFind in the treatment of Rotor Syndrome. Her top areas of expertise are Chronic Familial Neutropenia, Paget Disease of the Breast, Hemangioma Thrombocytopenia Syndrome, Bone Marrow Aspiration, and Bone Graft. Dr. Venuturumilli is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
NTR University Of Health Sciences, Vijayawada Osmania Medical College, 1991
Residency
Beaumont Hospital
Specialties
Oncology
Licenses
Pediatrics in MI
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Beaumont Hospital
Hospital Affiliations
Corewell Health William Beaumont University Hospital
Corewell Health Beaumont Troy Hospital
Languages Spoken
English
Hindi
Kannada
Tamil
Telugu
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Hematology Oncology Consultants Division of Michigan Healthcare Professionals PC
3577 West 13 Mile Road, Suite 103, Royal Oak, MI 48073
Other Locations
Hematology Oncology Consultants
4550 Investment Drive, Suite B120, Troy, MI 48098
Hematology Oncology Consultants
6770 Dixie Highway, Suite 106A, Clarkston, MI 48346

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

2 Total Publications

Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
Journal: Acta oncologica (Stockholm, Sweden)
Published: June 05, 2012
Similar Doctors
Experienced in Rotor Syndrome
Dr. Mary H. Mcgrath
Pediatric Hematology Oncology | Hematology | Oncology
Experienced in Rotor Syndrome
Dr. Mary H. Mcgrath
Pediatric Hematology Oncology | Hematology | Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (31.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mary Mcgrath is a Pediatric Hematologist Oncology specialist and a Hematologist in Ann Arbor, Michigan. Dr. Mcgrath is rated as an Advanced provider by MediFind in the treatment of Rotor Syndrome. Her top areas of expertise are Factor 11 Deficiency, Hemophilic Arthropathy, Hemophilia A, and Platelet Storage Pool Deficiency. Dr. Mcgrath is currently accepting new patients.

Experienced in Rotor Syndrome
Dr. Rama Rao
Pediatrics | Pediatric Hematology Oncology | Hematology
Experienced in Rotor Syndrome
Dr. Rama Rao
Pediatrics | Pediatric Hematology Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (31.8 miles away)
Languages Spoken:
English
See accepted insurances

Rama Rao is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Rao is rated as an Advanced provider by MediFind in the treatment of Rotor Syndrome. Her top areas of expertise are Osteosarcoma, Chondrosarcoma, Neuroblastoma, Hereditary Neuroblastoma, and Bone Marrow Aspiration.

Experienced in Rotor Syndrome
Dr. David Svilar
Pediatrics | Pediatric Hematology Oncology | Hematology
Experienced in Rotor Syndrome
Dr. David Svilar
Pediatrics | Pediatric Hematology Oncology | Hematology
1500 E Medical Center Dr Rm D4202, 
Ann Arbor, MI 
 (31.7 miles away)
734-936-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Svilar is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Svilar is rated as an Experienced provider by MediFind in the treatment of Rotor Syndrome. His top areas of expertise are Sickle Cell Disease, Hereditary Spherocytosis, Febrile Neutropenia, and Shwartzman Phenomenon. Dr. Svilar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Venuturumilli's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 88 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile